PBCAR269A is a BCMA targeted allogeneic (donor-derived) CAR T-cell therapy being developed for multiple myeloma patients.
| SparkCures ID | 368 |
|---|---|
| Developed By | Precision BioSciences, Inc. |
| Generic Name | PBCAR269A |
| Treatment Classifications |
|
| Treatment Targets |